{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:38:50Z","timestamp":1792179530130,"version":"4.4.0"},"reference-count":41,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010582","name":"NCI","doi-asserted-by":"publisher","award":["P30 CA225520"],"award-info":[{"award-number":["P30 CA225520"]}],"id":[{"id":"10.13039\/100010582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010582","name":"NCI","doi-asserted-by":"publisher","award":["134128-IRG-19-142-01"],"award-info":[{"award-number":["134128-IRG-19-142-01"]}],"id":[{"id":"10.13039\/100010582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"crossref","award":["P30 CA225520"],"award-info":[{"award-number":["P30 CA225520"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"crossref","award":["134128-IRG-19-142-01"],"award-info":[{"award-number":["134128-IRG-19-142-01"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Nancy Johnson Records Chair and Kerley-Cade Endowed Chair","award":["P30 CA225520"],"award-info":[{"award-number":["P30 CA225520"]}]},{"name":"Nancy Johnson Records Chair and Kerley-Cade Endowed Chair","award":["134128-IRG-19-142-01"],"award-info":[{"award-number":["134128-IRG-19-142-01"]}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Cells"],"abstract":"<jats:p>Bladder cancer (BCa) is one of the most lethal genitourinary malignancies owing to its propensity for recurrence and poor survival. The biochemical pathway, signal transducer and activator of transcription 3 (STAT3), has gained significance as a molecular pathway that promotes proliferation, invasion, and chemoresistance. In this study, we explored the targeting of STAT3 with TTI-101 and SH5-07 in BCa and elucidated the mechanisms in three-dimensional (3D) spheroid and organoid models. We optimized the growth of spheroids from human, rat, and mouse BCa cell lines (J82, NBT-II, and MB49 respectively) and organoids from BBN (N-butyl-N-(4-hydroxybutyl)-nitrosamine)-induced rat bladder tumors. Cell viability was assessed using MTT and trypan blue assays. Intracellular ATP production, ROS production, and calcium AM (CA)\/EtBr staining were used to measure the spheroid and organoid inhibition and mitochondrial function. Western blot analysis was performed to evaluate the pharmacodynamic markers involved in cell proliferation, apoptosis, cancer stem cells (CSCs), and STAT3 signaling in BCa. We found that targeting STAT3 (using TTI-101 and SH5-07) significantly reduced the proliferation of BCa spheroids and organoids, which was accompanied by decreased expression of pSTAT3, Cyclin D1, and PCNA. Our data also demonstrated that treatment with STAT3 inhibitors induced ROS production and cell death in BCa spheroids and organoids. STAT3 inhibition-induced cell death was associated with the activation of caspase 3\/7 and PARP cleavage. Moreover, TTI-101 and SH5-07 target cancer stem cells by downregulating the expression of CD44 and CD133 in 3D models. This study provides the first evidence for the prevention of BCa with small-molecule inhibitors TTI-101 and SH5-07 via suppression of CSCs and STAT3 signaling.<\/jats:p>","DOI":"10.3390\/cells13171463","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T03:45:21Z","timestamp":1725248721000},"page":"1463","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Stat3 Inhibitors TTI-101 and SH5-07 Suppress Bladder Cancer Cell Survival in 3D Tumor Models"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1848-2779","authenticated-orcid":false,"given":"Surya","family":"Singh","sequence":"first","affiliation":[{"name":"Center for Cancer Prevention and Drug Development, Stephenson Cancer Center, Hem-Onc Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA"},{"name":"Stephenson Cancer Center, Hem-Onc Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal","family":"Pathuri","sequence":"additional","affiliation":[{"name":"Center for Cancer Prevention and Drug Development, Stephenson Cancer Center, Hem-Onc Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA"},{"name":"Stephenson Cancer Center, Hem-Onc Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Asch","sequence":"additional","affiliation":[{"name":"Stephenson Cancer Center, Hem-Onc Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5715-7979","authenticated-orcid":false,"given":"Chinthalapally","family":"Rao","sequence":"additional","affiliation":[{"name":"Center for Cancer Prevention and Drug Development, Stephenson Cancer Center, Hem-Onc Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA"},{"name":"Stephenson Cancer Center, Hem-Onc Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8896-4095","authenticated-orcid":false,"given":"Venkateshwar","family":"Madka","sequence":"additional","affiliation":[{"name":"Center for Cancer Prevention and Drug Development, Stephenson Cancer Center, Hem-Onc Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA"},{"name":"Stephenson Cancer Center, Hem-Onc Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of bladder cancer in 2023: A systematic review of risk factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_2","first-page":"17","article-title":"Cancer Statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41467-023-37568-9","article-title":"Expression-Based Subtypes Define Pathologic Response to Neoadjuvant Immune-Checkpoint Inhibitors in Muscle-Invasive Bladder Cancer","volume":"14","author":"Robertson","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/1756287218814100","article-title":"The Continuing Role of Chemotherapy in the Management of Advanced Urothelial Cancer","volume":"10","author":"Duran","year":"2018","journal-title":"Ther. Adv. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6613","DOI":"10.1038\/sj.onc.1204086","article-title":"STAT Proteins: Novel Molecular Targets for Cancer Drug Discovery","volume":"19","author":"Turkson","year":"2000","journal-title":"Oncogene"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10151","DOI":"10.1073\/pnas.0604042103","article-title":"STAT3: A Multifaceted Oncogene","volume":"103","author":"Levy","year":"2006","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1158\/0008-5472.CAN-11-3195","article-title":"Stat3 Activation in Urothelial Stem Cells Leads to Direct Progression to Invasive Bladder Cancer","volume":"72","author":"Ho","year":"2012","journal-title":"Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Mirzaei, S., Gholami, M.H., Mahabady, M.K., Nabavi, N., Zabolian, A., Banihashemi, S.M., Haddadi, A., Entezari, M., Hushmandi, K., and Makvandi, P. (2021). Pre-Clinical Investigation of STAT3 Pathway in Bladder Cancer: Paving the Way for Clinical Translation. Biomed. Pharmacother., 133.","DOI":"10.1016\/j.biopha.2020.111077"},{"key":"ref_9","unstructured":"(2020). Cancer Cells Stemness: A Doorstep to Targeted Therapy. Biochim. Biophys. Acta. Mol. Basis. Dis., 1866."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1593\/neo.05394","article-title":"Stem-like Cells in Bone Sarcomas: Implications for Tumorigenesis","volume":"7","author":"Gibbs","year":"2005","journal-title":"Neoplasia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1172\/JCI44745","article-title":"The JAK2\/STAT3 Signaling Pathway Is Required for Growth of CD44+CD24\u2013 Stem Cell\u2013like Breast Cancer Cells in Human Tumors","volume":"121","author":"Marotta","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1245\/s10434-018-6706-0","article-title":"Predictive Value of CD44 in Muscle-Invasive Bladder Cancer and Its Relationship with IL-6 Signaling","volume":"25","author":"Wu","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/01.XEJ.0000520912.41715.09","article-title":"CD133 and CD44 as Cancer Stem Cell Markers in Bladder Carcinoma","volume":"37","author":"Wasfy","year":"2017","journal-title":"Egypt. J. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40495-023-00326-y","article-title":"Bladder Cancer Prevention: Potential Molecular Targets and Their Clinically Relevant Agents","volume":"9","author":"Singh","year":"2023","journal-title":"Curr. Pharmacol. Rep."},{"key":"ref_15","first-page":"1205","article-title":"Evaluation of the STAT3 Inhibitor GLG-302 for the Prevention of Estrogen Receptor-Positive and -Negative Mammary Cancers","volume":"42","author":"Shoemaker","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Kasembeli, M.M., Singhmar, P., Ma, J., Edralin, J., Tang, Y., Adams, C., Heijnen, C.J., Kavelaars, A., and Tweardy, D.J. (2021). TTI-101: A Competitive Inhibitor of STAT3 That Spares Oxidative Phosphorylation and Reverses Mechanical Allodynia in Mouse Models of Neuropathic Pain. Biochem. Pharmacol., 192.","DOI":"10.1016\/j.bcp.2021.114688"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1158\/0008-5472.CAN-14-3558","article-title":"Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes in Vitro and in Vivo","volume":"76","author":"Yue","year":"2016","journal-title":"Cancer Res."},{"key":"ref_18","first-page":"910","article-title":"2D and 3D Cell Cultures\u2014A Comparison of Different Types of Cancer Cell Cultures","volume":"14","author":"Kolenda","year":"2018","journal-title":"Arch. Med Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/cts.13066","article-title":"3D Cell Culture Models: Drug Pharmacokinetics, Safety Assessment, and Regulatory Consideration","volume":"14","author":"Wang","year":"2021","journal-title":"Clin Transl. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/1087057117696795","article-title":"Three-Dimensional Cell Cultures in Drug Discovery and Development","volume":"22","author":"Fang","year":"2017","journal-title":"SLAS Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"115286","DOI":"10.1016\/j.biopha.2023.115286","article-title":"Anti-Cancer Effect of a Phytochemical Compound-7R-Acetylmelodorinol-against Triple-Negative Breast Cancer Cells","volume":"166","author":"Thepmalee","year":"2023","journal-title":"Biomed Pharmacother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1158\/1940-6207.CAPR-19-0339","article-title":"Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers","volume":"13","author":"Mohammed","year":"2020","journal-title":"Cancer Prev. Res."},{"key":"ref_23","first-page":"58345","article-title":"3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer","volume":"139","author":"Wang","year":"2018","journal-title":"J. Vis. Exp."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.urolonc.2017.11.024","article-title":"Ex Vivo Culture of Tumor Cells from N-Methyl-N-Nitrosourea-Induced Bladder Cancer in Rats: Development of Organoids and an Immortalized Cell Line","volume":"36","author":"Yoshida","year":"2018","journal-title":"Urol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/ijc.26475","article-title":"Potential Role of Hsp90 Inhibitors in Overcoming Cisplatin Resistance of Bladder Cancer-Initiating Cells","volume":"131","author":"Tatokoro","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Benerini Gatta, L., Melocchi, L., Bugatti, M., Missale, F., Lonardi, S., Zanetti, B., Cristinelli, L., Belotti, S., Simeone, C., and Ronca, R. (2019). Hyper-Activation of STAT3 Sustains Progression of Non-Papillary Basal-Type Bladder Cancer via FOSL1 Regulome. Cancers, 11.","DOI":"10.3390\/cancers11091219"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"14016","DOI":"10.1073\/pnas.0906549106","article-title":"Identification, Molecular Characterization, Clinical Prognosis, and Therapeutic Targeting of Human Bladder Tumor-Initiating Cells","volume":"106","author":"Chan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41467-024-45132-2","article-title":"The IL6\/JAK\/STAT3 Signaling Axis Is a Therapeutic Vulnerability in SMARCB1-Deficient Bladder Cancer","volume":"15","author":"Amara","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.3892\/or.2017.5902","article-title":"STAT3 Inhibition by WP1066 Suppresses the Growth and Invasiveness of Bladder Cancer Cells","volume":"38","author":"Tsujita","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.2147\/OTT.S112566","article-title":"Monitoring the Effects of Doxorubicin on 3D-Spheroid Tumor Cells in Real-Time","volume":"9","author":"Baek","year":"2016","journal-title":"OncoTargets Ther."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Mittler, F., Obe\u00efd, P., Rulina, A.V., Haguet, V., Gidrol, X., and Balakirev, M.Y. (2017). High-Content Monitoring of Drug Effects in a 3D Spheroid Model. Front. Oncol., 7.","DOI":"10.3389\/fonc.2017.00293"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Jung, K.B., Kwon, O., Lee, M.-O., Lee, H., Son, Y.S., Habib, O., Oh, J.-H., Cho, H.-S., Jung, C.-R., and Kim, J. (2019). Blockade of STAT3 Causes Severe in Vitro and in Vivo Maturation Defects in Intestinal Organoids Derived from Human Embryonic Stem Cells. J. Clin. Med., 8.","DOI":"10.3390\/jcm8070976"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Fiorillo, M., \u00d3zsv\u00e1ri, B., Sotgia, F., and Lisanti, M.P. (2021). High ATP Production Fuels Cancer Drug Resistance and Metastasis: Implications for Mitochondrial ATP Depletion Therapy. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.740720"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.neo.2021.10.003","article-title":"STAT3 as a Mediator of Oncogenic Cellular Metabolism: Pathogenic and Therapeutic Implications","volume":"23","author":"Frank","year":"2021","journal-title":"Neoplasia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.bbadis.2016.11.010","article-title":"Mitochondrial Dysfunction and Oxidative Stress in Metabolic Disorders\u2014A Step towards Mitochondria Based Therapeutic Strategies","volume":"1863","author":"Bhatti","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/ars.2015.6418","article-title":"Nimbolide-Induced Oxidative Stress Abrogates STAT3 Signaling Cascade and Inhibits Tumor Growth in Transgenic Adenocarcinoma of Mouse Prostate Model","volume":"24","author":"Zhang","year":"2016","journal-title":"Antioxid. Redox Signal."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1172\/JCI0215650","article-title":"What Does Stat3 Do?","volume":"109","author":"Levy","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_38","first-page":"2585","article-title":"Overview of the STAT-3 Signaling Pathway in Cancer and the Development of Specific Inhibitors (Review)","volume":"19","author":"Gu","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/sj.cdd.4401160","article-title":"Many Cuts to Ruin: A Comprehensive Update of Caspase Substrates","volume":"10","author":"Fischer","year":"2003","journal-title":"Cell Death Differ."},{"key":"ref_40","first-page":"3976","article-title":"Specific Proteolytic Cleavage of Poly(ADP-Ribose) Polymerase: An Early Marker of Chemotherapy-Induced Apoptosis","volume":"53","author":"Kaufmann","year":"1993","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"66668","DOI":"10.18632\/oncotarget.19112","article-title":"Bladder Cancer Stem Cells: Clonal Origin and Therapeutic Perspectives","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"}],"updated-by":[{"DOI":"10.3390\/cells14040299","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000}}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/17\/1463\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T14:53:37Z","timestamp":1754232817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/17\/1463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,31]]},"references-count":41,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["cells13171463"],"URL":"https:\/\/doi.org\/10.3390\/cells13171463","relation":{"correction":[{"id-type":"doi","id":"10.3390\/cells14040299","asserted-by":"object"}]},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,31]]}}}